• Revisiting the SUMMIT Trial | JACC Deep Dive

  • May 6 2025
  • Duración: 6 m
  • Podcast

Revisiting the SUMMIT Trial | JACC Deep Dive

  • Resumen

  • This JACC Deep Dive in our May 13 issue highlights new findings from the SUMMIT CKD study, showing that terzepatide improves symptoms, function, and weight in patients with HFpEF and obesity—regardless of kidney function. The analysis also underscores the importance of using both creatinine and cystatin C to better assess kidney health. Reviewers praised the study’s methodological rigor and dual focus, while noting the need for larger, long-term trials to confirm renal outcomes.

    Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre Revisiting the SUMMIT Trial | JACC Deep Dive

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.